Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 647

1.

Equally increased risk for metabolic syndrome in patients with bipolar disorder and schizophrenia treated with second-generation antipsychotics.

Correll CU, Frederickson AM, Kane JM, Manu P.

Bipolar Disord. 2008 Nov;10(7):788-97. doi: 10.1111/j.1399-5618.2008.00625.x.

PMID:
19032710
[PubMed - indexed for MEDLINE]
2.

Typical and atypical antipsychotics differentially affect long-term incidence rates of the metabolic syndrome in first-episode patients with schizophrenia: a retrospective chart review.

De Hert M, Schreurs V, Sweers K, Van Eyck D, Hanssens L, Sinko S, Wampers M, Scheen A, Peuskens J, van Winkel R.

Schizophr Res. 2008 Apr;101(1-3):295-303. doi: 10.1016/j.schres.2008.01.028. Epub 2008 Mar 4.

PMID:
18299188
[PubMed - indexed for MEDLINE]
3.

Metabolic effects of second-generation antipsychotics in bipolar youth: comparison with other psychotic and nonpsychotic diagnoses.

Moreno C, Merchán-Naranjo J, Alvarez M, Baeza I, Alda JA, Martínez-Cantarero C, Parellada M, Sánchez B, de la Serna E, Giráldez M, Arango C.

Bipolar Disord. 2010 Mar;12(2):172-84. doi: 10.1111/j.1399-5618.2010.00797.x.

PMID:
20402710
[PubMed - indexed for MEDLINE]
4.

Metabolic syndrome and serum homocysteine in patients with bipolar disorder and schizophrenia treated with second generation antipsychotics.

Vuksan-Ćusa B, Jakovljević M, Sagud M, Mihaljević Peleš A, Marčinko D, Topić R, Mihaljević S, Sertić J.

Psychiatry Res. 2011 Aug 30;189(1):21-5. doi: 10.1016/j.psychres.2010.11.021. Epub 2011 Jan 7.

PMID:
21216014
[PubMed - indexed for MEDLINE]
5.

Patients taking medications for bipolar disorder are more prone to metabolic syndrome than Korea's general population.

Lee NY, Kim SH, Cho B, Lee YJ, Chang JS, Kang UG, Kim YS, Ahn YM.

Prog Neuropsychopharmacol Biol Psychiatry. 2010 Oct 1;34(7):1243-9. doi: 10.1016/j.pnpbp.2010.06.029. Epub 2010 Jul 3.

PMID:
20599461
[PubMed - indexed for MEDLINE]
6.

Cardiovascular and metabolic risk in outpatients with schizophrenia treated with antipsychotics: results of the CLAMORS Study.

Bobes J, Arango C, Aranda P, Carmena R, Garcia-Garcia M, Rejas J; CLAMORS Study Collaborative Group.

Schizophr Res. 2007 Feb;90(1-3):162-73. Epub 2006 Nov 21.

PMID:
17123783
[PubMed - indexed for MEDLINE]
7.

Therapeutic drug and cardiovascular disease risk monitoring in patients with bipolar disorder.

Kilbourne AM, Post EP, Bauer MS, Zeber JE, Copeland LA, Good CB, Pincus HA.

J Affect Disord. 2007 Sep;102(1-3):145-51. Epub 2007 Feb 5.

PMID:
17276514
[PubMed - indexed for MEDLINE]
8.

Metabolic syndrome and the risk of coronary heart disease in 367 patients treated with second-generation antipsychotic drugs.

Correll CU, Frederickson AM, Kane JM, Manu P.

J Clin Psychiatry. 2006 Apr;67(4):575-83.

PMID:
16669722
[PubMed - indexed for MEDLINE]
9.

The METEOR study: frequency of metabolic disorders in patients with schizophrenia. Focus on first and second generation and level of risk of antipsychotic drugs.

Falissard B, Mauri M, Shaw K, Wetterling T, Doble A, Giudicelli A, De Hert M.

Int Clin Psychopharmacol. 2011 Nov;26(6):291-302. doi: 10.1097/YIC.0b013e32834a5bf6.

PMID:
21876442
[PubMed - indexed for MEDLINE]
10.

Metabolic monitoring in veterans with schizophrenia-related disorders and treated with second-generation antipsychotics: findings from a Veterans Affairs-based population.

Hsu C, Ried LD, Bengtson MA, Garman PM, McConkey JR, Rahnavard F.

J Am Pharm Assoc (2003). 2008 May-Jun;48(3):393-400. doi: 10.1331/JAPhA.2008.07007.

PMID:
18595825
[PubMed - indexed for MEDLINE]
11.
12.

[Prescribing patterns of antipsychotics in 13 French psychiatric hospitals].

Bret P, Bret MC, Queuille E.

Encephale. 2009 Apr;35(2):129-38. doi: 10.1016/j.encep.2008.03.007. Epub 2008 Jul 7. French.

PMID:
19393381
[PubMed - indexed for MEDLINE]
13.

Association of adiponectin and metabolic syndrome among patients taking atypical antipsychotics for schizophrenia: a cohort study.

Bai YM, Chen TT, Yang WS, Chi YC, Lin CC, Liou YJ, Wang YC, Su TP, Chou P, Chen JY.

Schizophr Res. 2009 Jun;111(1-3):1-8. doi: 10.1016/j.schres.2009.03.014. Epub 2009 May 5.

PMID:
19409756
[PubMed - indexed for MEDLINE]
14.

Risk of diabetes mellitus associated with atypical antipsychotic use among patients with bipolar disorder: A retrospective, population-based, case-control study.

Guo JJ, Keck PE Jr, Corey-Lisle PK, Li H, Jiang D, Jang R, L'Italien GJ.

J Clin Psychiatry. 2006 Jul;67(7):1055-61.

PMID:
16889448
[PubMed - indexed for MEDLINE]
15.

Time to psychiatric hospitalization in patients with bipolar disorder treated with a mood stabilizer and adjunctive atypical antipsychotics: a retrospective claims database analysis.

Kim E, Maclean R, Ammerman D, Jing Y, Pikalov A, You M, Van-Tran Q, L'Italien G.

Clin Ther. 2009 Apr;31(4):836-48. doi: 10.1016/j.clinthera.2009.04.022.

PMID:
19446157
[PubMed - indexed for MEDLINE]
16.

Management of antipsychotic-induced weight gain: prospective naturalistic study of the effectiveness of a supervised exercise programme.

Poulin MJ, Chaput JP, Simard V, Vincent P, Bernier J, Gauthier Y, Lanctôt G, Saindon J, Vincent A, Gagnon S, Tremblay A.

Aust N Z J Psychiatry. 2007 Dec;41(12):980-9.

PMID:
17999270
[PubMed - indexed for MEDLINE]
17.

Weight gain and metabolic effects of mood stabilizers and antipsychotics in pediatric bipolar disorder: a systematic review and pooled analysis of short-term trials.

Correll CU.

J Am Acad Child Adolesc Psychiatry. 2007 Jun;46(6):687-700. Review.

PMID:
17513981
[PubMed - indexed for MEDLINE]
18.

Efficacy and safety of second-generation antipsychotics in children and adolescents with psychotic and bipolar spectrum disorders: comprehensive review of prospective head-to-head and placebo-controlled comparisons.

Fraguas D, Correll CU, Merchán-Naranjo J, Rapado-Castro M, Parellada M, Moreno C, Arango C.

Eur Neuropsychopharmacol. 2011 Aug;21(8):621-45. doi: 10.1016/j.euroneuro.2010.07.002. Epub 2010 Aug 10. Review.

PMID:
20702068
[PubMed - indexed for MEDLINE]
19.

Dyslipidemia independent of body mass in antipsychotic-treated patients under real-life conditions.

Birkenaes AB, Birkeland KI, Engh JA, Faerden A, Jonsdottir H, Ringen PA, Friis S, Opjordsmoen S, Andreassen OA.

J Clin Psychopharmacol. 2008 Apr;28(2):132-7. doi: 10.1097/JCP.0b013e318166c4f7.

PMID:
18344722
[PubMed - indexed for MEDLINE]
20.

Metabolic syndrome with different antipsychotics: a multicentre cross-sectional study.

Cerit C, Vural M, Bos Gelmez SÜ, Ozten E, Aker AT, Yıldız M.

Psychopharmacol Bull. 2010;43(4):22-36.

PMID:
21240150
[PubMed - indexed for MEDLINE]
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk